Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework

The burden of Progressive Fibrotic Interstitial lung disease across the UK

(2021) Thomas Simpson et al.   EUROPEAN RESPIRATORY JOURNAL

The natural history of progressive fibrosing interstitial lung diseases

(2020) K.K. Brown et al.   EUROPEAN RESPIRATORY JOURNAL

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review

(2020) Yet H. Khor et al.   European Respiratory Review

Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib

(2020) Shigeki Makino   Modern Rheumatology

Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions

(2019) Fanni Soikkeli et al.   VALUE IN HEALTH

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

(2019) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

(2017) Margaret Gamalo-Siebers et al.   PHARMACEUTICAL STATISTICS

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

(2017) Luca Richeldi et al.   THORAX

flexsurv: A Platform for Parametric Survival Modeling inR

(2016) Christopher Jackson   Journal of Statistical Software